CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion | +500 | $70.57 | $35K | 98,687 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Sale | −500 | $88.38 | $44K | 98,187 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion | +7,188 | $67.55 | $486K | 105,375 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Sale | −7,188 | $88.38 | $635K | 98,187 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion | +3,669 | $48.43 | $178K | 101,856 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Sale | −3,669 | $88.38 | $324K | 98,187 |
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion · Stock Option (Right to Buy) | −500 | 0 | ||
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion · Stock Option (Right to Buy) | −7,188 | 15,812 | ||
| 2020-08-17 | Sharp Shalini CFO & Executive Vice President | Exercise or conversion · Stock Option (Right to Buy) | −3,669 | 15,312 | ||
| 2020-08-10 | SIEGALL CLAY B Director | Sale | −9,750 | $85.01 | $829K | 2,550 |
| 2020-08-10 | SIEGALL CLAY B Director | Exercise or conversion | +1,596 | $40.37 | $64K | 4,146 |
| 2020-08-10 | SIEGALL CLAY B Director | Sale | −1,596 | $85.01 | $136K | 2,550 |
| 2020-08-10 | SIEGALL CLAY B Director | Exercise or conversion · Stock Option (Right to Buy) | −1,596 | 0 | ||
| 2020-08-07 | SIEGALL CLAY B Director | Exercise or conversion | +5,904 | $40.37 | $238K | 18,204 |
| 2020-08-07 | SIEGALL CLAY B Director | Exercise or conversion | +17,500 | $21.00 | $368K | 35,704 |
| 2020-08-07 | SIEGALL CLAY B Director | Sale | −23,404 | $85.55 | $2.0M | 12,300 |
| 2020-08-07 | SIEGALL CLAY B Director | Exercise or conversion · Stock Option (Right to Buy) | −5,904 | 1,596 | ||
| 2020-08-07 | SIEGALL CLAY B Director | Exercise or conversion · Stock Option (Right to Buy) | −17,500 | 0 | ||
| 2020-07-13 | KAKKIS EMIL D President & CEO | Sale | −40,000 | $85.35 | $3.4M | 2,419,741 |
| 2020-07-08 | Huizenga Theodore Alan SVP, Controller and PAO | Sale | −638 | $91.00 | $58K | 16,582 |
Page 25 of 32 · 632 trades